


- Amendments to the Claims -

Amend claims as follows:

1. (Currently amended) A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof, wherein

R¹ is (i) H, (ii) C₁-C₆ alkyl optionally substituted by 1 or 2 substituents each independently selected from phenyl, naphthyl and fluorenyl, said phenyl, naphthyl and fluorenyl being optionally substituted by C₁-C₆ alkyl, C₁-C₆ alkoxy, halo or cyano, or (iii) fluorenyl;

R² is H or C₁-C₆ alkyl;

either, R³ and R⁴, taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C₁-C₆ alkyl or C₃-C₈ cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by

-NR⁶R⁷ or -OR⁹,

or, R³ is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl or benzyl, said C₁-C₆ alkyl being optionally substituted by C₃-C₈ cycloalkyl, and R⁴ is

(a) C₁-C₆ alkyl, C₃-C₈ cycloalkyl or R¹⁵, said C₁-C₆ alkyl being optionally substituted by R¹⁵; or

(b) -(C₂-C₆ alkylene)-R⁸, or

(c) -(C₁-C₆ alkylene)-R¹³;

R⁵ is -CH₂OH or -CONHR¹⁴ -CONR¹⁴R¹⁴;

R⁶ and R⁷ are either each independently H or C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidinyl or piperidinyl, said azetidiny, pyrrolidinyl and piperidinyl being optionally substituted by C₁-C₆ alkyl;

R^8 is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, phenyl, C_1 - C_6 alkoxy-(C_1 - C_6)-alkyl, R^9R^9N -(C_1 - C_6)-alkyl, fluoro-(C_1 - C_6)-alkyl, $-CONR^9R^9$, $-COOR^9$ or C_2 - C_5 alkanoyl, optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C_1 - C_6)-alkoxy, halo, $-OR^9$, cyano, $-S(O)_mR^{10}$, $-NR^9R^9$, $-SO_2NR^9R^9$, $-NR^9COR^{10}$ or $-NR^9SO_2R^{10}$ and optionally benzo-fused, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C_2 - C_6 alkylene group by C_1 - C_6 alkyl, phenyl, C_1 - C_6 alkoxy-(C_2 - C_6)-alkyl, R^9R^9N -(C_2 - C_6)-alkyl, fluoro-(C_1 - C_6)-alkyl, C_2 - C_5 alkanoyl, $-COOR^{10}$, C_3 - C_8 cycloalkyl, $-SO_2R^{10}$, $-SO_2NR^9R^9$ or $-CONR^9R^9$, or (ii) $-NR^{11}R^{12}$;

R^9 is H, C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl or phenyl;

R^{10} is C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl or phenyl;

R^{11} is C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl or benzyl;

R^{12} is C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, phenyl, benzyl, fluoro-(C_1 - C_6)-alkyl, $-CONR^9R^9$, $-COOR^{10}$, $-COR^{10}$, $-SO_2R^{10}$ or $-SO_2NR^9R^9$, said C_1 - C_6 alkyl being optionally substituted by phenyl;

R^{13} is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo or cyano;

R^{14} is H or C_1 - C_6 alkyl optionally substituted by cyclopropyl;

R^{15} is azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by R^{13} , C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl or benzyl;

m is 0, 1 or 2;

X is $-CH_2-$ or $-CH_2CH_2-$; and

Y is CO, CS, SO_2 or $C=N(CN)$.

2. (Currently amended) A compound of the formula (I), as defined in claim 1, wherein

R^1 is H, C_1 - C_6 alkyl or fluorenyl, said C_1 - C_6 alkyl being optionally substituted by 1 or 2 substituents each independently selected from phenyl and naphthyl, said phenyl and naphthyl being optionally substituted by C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo or cyano;

R^2 is H or C_1 - C_6 alkyl;

either, R^3 and R^4 , taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or

homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by C₁-C₆ alkyl or C₃-C₈ cycloalkyl and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by

-NR⁶R⁷,

or, R³ is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl or benzyl and R⁴ is

(a) azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl, each being optionally substituted by C₁-C₆ alkyl, C₃-C₈ cycloalkyl or benzyl, or

(b) -(C₂-C₆ alkylene)-R⁸, or

(c) -(C₁-C₆ alkylene)-R¹³;

~~R⁶ is -CH₂OH or -CONR¹⁴R¹⁴;~~

R⁶ and R⁷ are either each independently H or C₁-C₆ alkyl or, taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidiny or piperidiny, said azetidiny, pyrrolidiny and piperidiny being optionally substituted by C₁-C₆ alkyl;

R⁸ is (i) azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homopiperazin-1-yl or tetrahydroisoquinolin-1-yl, each being optionally substituted on a ring carbon atom by C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, C₁-C₆ alkoxy-(C₁-C₆)-alkyl, R⁹R⁹N-(C₁-C₆)-alkyl, fluoro-(C₁-C₆)-alkyl, -CONR⁹R⁹, -COOR⁹ or C₂-C₅ alkanoyl, and optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C₁-C₆)-alkoxy, halo, -OR⁹, cyano, -S(O)_mR¹⁰, -NR⁹R⁹, -SO₂NR⁹R⁹, -NR⁹COR¹⁰ or -NR⁹SO₂R¹⁰, and said piperazin-1-yl and homopiperazin-1-yl being optionally substituted on the ring nitrogen atom not attached to the C₂-C₆ alkylene group by C₁-C₆ alkyl, phenyl, C₁-C₆ alkoxy-(C₂-C₆)-alkyl, R⁹R⁹N-(C₂-C₆)-alkyl, fluoro-(C₁-C₆)-alkyl, C₂-C₅ alkanoyl, -COOR¹⁰, C₃-C₈ cycloalkyl, -SO₂R¹⁰, -SO₂NR⁹R⁹ or -CONR⁹R⁹, or

(ii) -NR¹¹R¹²;

R⁹ is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl or phenyl;

R¹⁰ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl or phenyl;

R¹¹ is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl or benzyl;

R¹² is H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, benzyl, fluoro-(C₁-C₆)-alkyl, -CONR⁹R⁹, -COOR¹⁰, C₂-C₅ alkanoyl or -SO₂NR⁹R⁹;

R¹³ is phenyl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, each being optionally substituted by C₁-C₆ alkyl, C₁-C₆ alkoxy, halo or cyano;

R¹⁴ is H or C₁-C₆ alkyl optionally substituted by cyclopropyl;

m is 0, 1 or 2;

X is -CH₂- or -CH₂CH₂-; and

Y is CO, CS, SO₂ or C=N(CN).

3. (Original) A compound as claimed in claim 1 wherein R¹ is C₁-C₆ alkyl optionally substituted by 1 or 2 substituents each independently selected from phenyl, naphthyl and fluorenyl, said phenyl, naphthyl and fluorenyl being optionally substituted by C₁-C₆ alkyl, C₁-C₆ alkoxy, halo or cyano.

4. (Original) A compound as claimed in claim 3 wherein R¹ is 2,2-diphenyleth-1-yl, 2,2-di(4-chlorophenyl)eth-1-yl, 2,2-di(3-chlorophenyl)eth-1-yl, 2,2-di(4-methylphenyl)eth-1-yl, 2,2-di(3-methylphenyl)eth-1-yl, naphth-1-ylmethyl or fluoren-9-ylmethyl.

5. (Original) A compound as claimed in claim 1 or claim 2 wherein R² is H or C₁-C₄ alkyl.

6. (Original) A compound as claimed in claim 5 wherein R² is H or methyl.

7. (Original) A compound as claimed in claim 1 or claim 2 wherein R³ is H or C₁-C₆ alkyl.

8. (Original) A compound as claimed in claim 7 wherein R³ is H or methyl.

9. (Original) A compound as claimed in claim 1 wherein R⁴ is (a) C₁-C₄ alkyl substituted by -R¹⁵, C₃-C₆ cycloalkyl or -R¹⁵; or (b) -(C₂-C₄ alkylene)-R⁸, or (c) -(C₁-C₄ alkylene)-R¹³.

10. (Original) A compound as claimed in claim 9 wherein R⁴ is -CH₂R¹⁵, cyclohexyl, -R¹⁵, -CH₂CH₂R⁸, -CH₂R¹³ or -CH₂CH₂R¹³.

11. (Original) A compound as claimed in claim 1 or claim 2 wherein R⁵ is -CH₂OH or -CONH(C₁-C₆ alkyl).

12. (Original) A compound as claimed in claim 11 wherein R⁵ is -CH₂OH or -CONHCH₂CH₃.

13. (Original) A compound as claimed in claim 1 wherein R⁸ is (i) piperidin-1-yl, optionally substituted on a ring carbon atom by C₁-C₆ alkyl, C₃-C₈ cycloalkyl, phenyl, C₁-C₆ alkoxy-(C₁-C₆)-alkyl, R⁹R⁹N-(C₁-C₆)-alkyl, fluoro-(C₁-C₆)-alkyl, -CONR⁹R⁹, -COOR⁹ or C₂-C₅ alkanoyl, optionally substituted on a ring carbon atom not adjacent to a ring nitrogen atom by fluoro-(C₁-C₆)-alkoxy, halo, -OR⁹, cyano, -S(O)_mR¹⁰, -NR⁹R⁹, -SO₂NR⁹R⁹, -NR⁹COR¹⁰ or -NR⁹SO₂R¹⁰ and optionally benzo-fused, or (ii) -NR¹¹R¹².

14. (Original) A compound as claimed in claim 13 wherein R⁸ is piperidin-1-yl, 4-(2-propyl)piperidin-1-yl, 2,2,6,6-tetramethylpiperidin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl or -NR¹¹R¹².
15. (Original) A compound as claimed in claim 1 or claim 2 wherein R¹¹ is C₁-C₆ alkyl or C₃-C₈ cycloalkyl.
16. (Original) A compound as claimed in claim 15 wherein R¹¹ is -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -CH(CH₂CH₃)₂, cyclohexyl or cyclopentyl.
17. (Original) A compound as claimed in claim 1 wherein R¹² is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, -COR¹⁰ or -SO₂R¹⁰ said C₁-C₆ alkyl being optionally substituted by phenyl.
18. (Original) A compound as claimed in claim 17 wherein R¹² is -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -CH(CH₂CH₃)₂, -C(CH₃)₂Ph, -SO₂Ph, -COPh, cyclohexyl or cyclopentyl.
19. (Original) A compound as claimed in claim 1 or claim 2 wherein R¹³ is phenyl or pyridin-2-yl, each being optionally substituted by C₁-C₆ alkyl, C₁-C₆ alkoxy, halo or cyano.
20. (Original) A compound as claimed in claim 18 wherein R¹³ is phenyl or pyridin-2-yl.
21. (Original) A compound as claimed in claim 1 wherein R¹⁵ is pyrrolidin-3-yl or piperidin-4-yl, each being optionally substituted by R¹³, C₁-C₆ alkyl, C₃-C₈ cycloalkyl or benzyl.
22. (Original) A compound as claimed in claim 21 wherein R¹⁵ is 1-benzyl-piperidin-4-yl, (1-benzyl-piperidin-4-yl)methyl, 1-(2-pyridinyl)piperidin-4-yl, or 1-benzyl-pyrrolidin-3-yl.
23. (Original) A compound as claimed in claim 1 or claim 2 wherein X is -CH₂-.
24. (Original) A compound as claimed in claim 1 or claim 2 wherein Y is CO or C=N(CN).
25. (Original) A compound as claimed in claim 1 which is selected from the group consisting of:
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)-*N*-[2-(diisopropylamino)ethyl] urea;
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)-*N*-[2-(1-piperidinyl)ethyl]urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-(diisopropylamino)ethyl]amino]carbonyl]amino] methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino)methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[(*E*)-(cyanoimino){2-(1-piperidinyl)ethyl]amino]methyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[(benzylamino)carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[(cyclohexylamino)carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-[benzoyl(isopropyl)amino]ethyl]amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[isopropyl(phenylsulfonyl)amino]ethyl]amino]carbonyl]amino]methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl)-*N*-methyl-*N*-[2-(2-pyridinyl) ethyl]urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[(1-benzyl-4-piperidinyl)amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[(1-ethylpropyl)(isobutyl)amino]ethyl]amino]carbonyl]amino]methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl)-*N*-{2-[(1-ethylpropyl)(isobutyl)amino]ethyl}urea;

N-[2-(3,4-dihydro-2(1*H*)-isoquinolinyl)ethyl]-*N*-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}urea;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-(3,4-dihydro-2(1*H*)-isoquinoliny]ethyl)amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-(dibutylamino)ethyl]amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-[cyclopentyl(isopropyl)amino]ethyl]amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{2-[cyclopentyl(isopropyl)amino]ethyl}-*N'*-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}urea;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-[[methyl([2-(1-piperidinyl)ethyl]amino)carbonyl]amino]methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

(2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-*tert*-butyl(cyclohexyl)amino]ethyl]amino]carbonyl]amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-{2-[*tert*-butyl(cyclohexyl)amino]ethyl}-*N'*-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}urea;

N-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}-*N'*-[1-(2-pyridinyl)-4-piperidinyl]urea;

N-[(1-benzyl-4-piperidinyl)methyl]-*N'*-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}urea;

N-[(1-benzyl-4-piperidinyl)methyl]-*N'*-{[9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl]methyl}urea;

(2*S*,3*S*,4*R*,5*R*)-5-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[isopropyl(1-methyl-1-phenylethyl)amino]ethyl]amino]carbonyl]amino]methyl)-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;

N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)-*N'*-{2-[isopropyl(1-methyl-1-phenylethyl)amino]ethyl}urea;
N-[2-(dicyclopentylamino)ethyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)urea;
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(9*H*-fluoren-9-ylmethyl)amino]-9*H*-purin-2-yl)methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;
N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)-*N'*-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]urea;
(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{{{[2-(4-isopropyl-1-piperidinyl)ethyl]amino}carbonyl}amino]methyl)-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
(2*S*,3*S*,4*R*,5*R*)-5-(6-[(2,2-diphenylethyl)amino]-2-{{{[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]amino}carbonyl}amino]methyl)-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
N-[(3*R*)-1-benzylpyrrolidinyl]-*N'*-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)urea;
(2*S*,3*S*,4*R*,5*R*)-5-{2-{{{[(3*R*)-1-benzylpyrrolidinyl]amino}carbonyl}amino]methyl}-6-[(2,2-diphenylethyl)amino]-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
(2*S*,3*S*,4*R*,5*R*)-5-(6-{[2,2-bis(4-chlorophenyl)ethyl]amino}-2-{{{[2-(diisopropylamino)ethyl]amino}carbonyl}amino]methyl)-9*H*-purin-9-yl)-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
N-({6-{[2,2-bis(4-chlorophenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl)methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;
N-({6-{[2,2-bis(3-methylphenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl)methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;
N-({6-{[2,2-bis(3-chlorophenyl)ethyl]amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl)methyl)-*N'*-[2-(diisopropylamino)ethyl]urea;


N-({6-{{2,2-bis(3-methylphenyl)ethyl}amino}-9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-9*H*-purin-2-yl)methyl}-*N*-[2-(diisopropylamino)ethyl]urea; and
 (2*S*,3*S*,4*R*,5*R*)-5-{2-[[[2-(Diisopropylamino)ethyl]amino]carbonyl]amino)methyl}-6-[(1-naphthylmethyl)amino]-9*H*-purin-9-yl]-*N*-ethyl-3,4-dihydroxytetrahydro-2-furancarboxamide;
 and the pharmaceutically acceptable salts and solvates thereof.

26. (Previously presented) A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable excipient, diluent or carrier.

27. - 42. (Canceled)


43. (Previously presented) A process for preparing a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising

(a) deprotecting a compound of the formula




wherein R¹, R², R³, R⁴, X and Y are as defined in claim 1 and either P¹, P² and P³, when taken separately, are protecting groups or, P¹ and P², when taken together are a protecting group and P³ is a protecting group, the protecting groups being removed together or sequentially; or

(b) deprotecting a compound of the formula




wherein R^1 , R^2 , R^3 , R^4 , X and Y are as defined in claim 1 and either P^1 and P^2 , when taken separately, are protecting groups or, P^1 and P^2 , when taken together are a protecting group, the protecting groups P^1 and P^2 , when taken separately, being removed either together or sequentially; or

(c) deprotecting a compound of the formula



wherein P^3 is a protecting group and R^1 , R^2 , R^3 , R^4 , X and Y are as defined in claim 1; or


(d) deprotecting a compound of the formula



wherein R^1 , R^2 , R^3 , R^4 , R^{14} , X and Y are as defined in claim 1 and either P^1 and P^2 , when taken separately, are protecting groups or, P^1 and P^2 , when taken together are a protecting group, the protecting groups P^1 and P^2 , when taken separately, being removed either together or sequentially;


any one of said processes (a) to (d) being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

44. (Previously presented) A process for preparing a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising reacting a compound of the formula




wherein R¹, R², R⁵ and X are as defined in claim 1 with

(a) a compound of the formula



wherein R³ and R⁴ are as defined in claim 1 and L¹ is a suitable leaving group; or


(b) a compound of the formula




wherein R³ and R⁴ are as defined in claim 1 and L⁹ is a suitable leaving group; or

(c) a compound of the formula

wherein R³ and R⁴ are as defined in claim 1 and L⁸ is a suitable leaving group; or



(d) a compound of the formula




wherein R³ and R⁴ are as defined in claim 1 and L¹³ is a suitable leaving group;

said process being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

45. (Previously presented) A process for preparing a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising

(a) reacting a compound of the formula




wherein R^1 , R^2 , R^5 and X are as defined in claim 1 and L^{20} is a suitable leaving group with a compound of the formula




wherein R^3 and R^4 are as defined in claim 1; or

(b) reacting a compound of the formula




wherein R^1 , R^2 , R^5 and X are as defined in claim 1 and L^{21} is a suitable leaving group with a compound of the formula




wherein R^3 and R^4 are as defined in claim 1; or

(c) reacting a compound of the formula




wherein R^1 , R^2 , R^5 and X are as defined in claim 1 and L^{22} is a suitable leaving group with a compound of the formula



wherein R^3 and R^4 are as defined in claim 1;

any one of said processes (a) to (c) being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

46. (Previously presented) A process for preparing a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, comprising acylating or sulphonylating a compound of the formula



wherein R^1 , R^2 , R^3 , R^5 , R^{11} , X and Y are as defined in claim 1;

said process being optionally followed by the conversion of the compound of the formula (I) to a pharmaceutically acceptable salt thereof.

47. (Canceled)

48. (Previously presented) A process of claim 45 wherein, in step (a), L^{20} is imidazol-1-yl.

49. (Previously presented) A process of claim 45 wherein, in step (b), L^{21} is methylthio or imidazol-1-yl.

50. (Previously presented) A process of claim 45 wherein, in step (c), L^{22} is methylthio.

51. (Previously presented) A process of claim 44 wherein, in step (a), L^1 is imidazol-1-yl.

52. (Previously presented) A process of claim 44 wherein, in step (b),
L⁹ is chloro.
53. (Previously presented) A process of claim 44 wherein, in step (c),
L⁸ is methylthio or imidazol-1-yl.
54. (Previously presented) A process of claim 44 wherein, in step (d),
L¹³ is methylthio.